The good news about vaccines is in the queue

While the world fears a third wave of infections, vaccine news continues to come.

In many countries, including Norway, the infection is now on the rise. New and more infectious types are emerging. In many countries, at least not in EU countries, impatience is high. Demands for speeding up vaccination are growing in force.

Recently, there has been a lot of big and small news worldwide about vaccines. Together, they can ease the situation and reduce the time the world is in a kind of emergency.

A plug and refrigerator

Probably the biggest good news on this front U.S. approval for a third vaccine. The U.S. Drug Administration announced the decision last weekend. The new vaccine was developed by Johnson Biotech, a company owned by Johnson & Johnson (J&J).

It has two obvious advantages: One dose is enough. You do not need to show patients twice. It can also withstand good storage in the refrigerator for up to two months. This makes delivery easier.

FUC: Very good

Infection protection with J&J seems to be slightly weaker than that of Moderna and Pfizer-Biotech. Still, it must be protected 85 percent Against severe symptoms. The results also indicate 100 percent consequences for hospitalization and death.

– This is a good vaccine. “Now we need as many good vaccines as possible,” said Anthony Fucci, an American epidemiologist.

Like World War II

Later this week, US President Joe Biden also spoke about the Johnson Syringe. He had a message that really gave him hope. J&J really struggled to speed up production.

Biden used a crisis regulation, which is used during wartime. This can be used to collaborate with competitors. It will now manufacture vaccine doses for pharmaceutical company Merck J&J.

“This is the kind of cooperation we saw during World War II,” Biden said.

– Enough for everyone in May

Merck is one of three international vaccine companies that have not won the vaccine race. The other two are glycosmithkline (GSK) and Sanofi. Sanofi has promised to compile a scale for Pfizer-Biotech. G.S.K. Collaborate for its part with a candidate who is on the rising side: Kurewak.

In the United States, the crisis action with Merck and J&J has raised hopes for the future. Biden Announced By the end of May the country will now have sufficient quantities for all people. Prior to this, the rating was at the end of July.

This may ultimately be good news for other countries as well. Neighboring countries Canada and Mexico have so far tried in vain to import quantities from the United States.

Tolerates normal frost

There is also good news about other types of vaccines. When Pfizer-Biotech introduced its vaccine, it had one obvious drawback: it had to be stored at 70 degrees below zero. It is then dissolved shortly before being pierced into the hands of the people.

This created major problems for the distribution. Not least, it can be diverted to small places far away from large public centers.

The American Pharmaceuticals Company has now reconsidered the case. The vaccine can be kept in a normal freezer for up to two weeks.

More seniors are available

The vaccine from Astra Geneca is one-third approved in the European Union. But it is doubtful whether the elderly can use it. Therefore, many countries do not provide this to people over 65 or in some cases over 55 years of age.

Now this is changing. The reason for the new studies on vaccination in the UK. Among other things, it was 60 percent effective against Govt symptoms after a single dose in people over 70 years of age. The vaccine also greatly reduced the risk of hospitalization for the elderly.

Now many countries are opening up to give this vaccine to their adult population. Germany and Sweden decided on Thursday. France, Belgium and Italy had already relaxed their restrictions. On Friday, Denmark followed. Norway considers that as well.

German authorities also recommend Wait 12 weeks By giving the next dose. This should give a better effect than having less time between syringes. The advantage of this is that it can go very fast to give the first dose to more people.

Sputnik and the European Union?

Russia is running its own vaccination program. In August last year, Sputnik V was approved in his home country. Abroad, experts were skeptical. This was approved before the test was completed. Last month, however, a study in the UK showed The Lancet Sputnik V is 92 percent efficient.

Many EU countries in the East have bought it. The EU is now deliberating whether to approve it across the Union.

Vaccines work

The vaccines used have shown good results in large trials. However, since they are brand new, they have not been tried in real life by the entire population.

In Israel, however, the numbers begin to rise.

The country launched its program in December. By February, 84 percent of those over the age of 70 had been stabbed. Of those under 50, only ten percent were vaccinated. Israel compared the need for a respirator in the two groups. It was used as a measure of whether vaccines prevent serious disease.

Conclusion: Vaccines work well even outside of controlled research trials.